Proactive Investors - Run By Investors For Investors

Imugene to be granted patent for cancer vaccine in Israel

Imugene to be granted patent for cancer vaccine in Israel

Imugene Limited (ASX:IMU) may trade firmer after the Israeli Patent Office issued an Intention to Grant for its proprietary cancer vaccine, HER-Vaxx.

The patent will protect specific cancer vaccine formulations in Israel until 2027.

HER-Vaxx stimulates a polyclonal antibody response to the HER-2/neu receptor, the same biomarker targeted by the $US6.9 billion per annum drug Herceptin®.

HER-2/neu is known to be over-expressed on various tumours including gastric, breast, ovarian and pancreatic cancers.

HERVaxx has completed a Phase 1 study in breast cancer; the next stage of development will be a Phase 2 study in gastric cancer, which is the second most common cause of cancer-related death in the world

Imugene secured full rights to manufacture the cancer immunotherapy as part of its acquisition of BioLife Science in December last year.

The first patent was assigned from Pevion Biotech of Switzerland, protecting Her-Vaxx in several major markets until 2030.

Imugene also holds an exclusive global license covering a patent for the virosome vaccine delivery platform, which is used in the vaccine's manufacture.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.


View full IMU profile View Profile

Imugene Ltd Timeline

October 19 2016

Related Articles

immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
blood samples in test tubes
October 26 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use